PRAME expression and its prognostic significance in invasive breast carcinoma

This publication has 28 references indexed in Scilit:

• Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
  The Lancet, 2014
• Tumor Subtype-Specific Cancer–Testis Antigens as Potential Biomarkers and Immunotherapeutic Targets for Cancers
  Cancer Immunology Research, 2014
• Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
  Nature Reviews Cancer, 2014
• Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
  Annals of Oncology, 2013
• The Cancer Testis Antigen PRAME As a Biomarker for Solid Tumor Cancer Management
  Biomarkers in Medicine, 2012
• Expression of MCSP and PRAME in conjunctival melanoma
  British Journal of Ophthalmology, 2010
• PRAME expression and clinical outcome of breast cancer
  British Journal of Cancer, 2008
• Prevalence and prognostic and predictive relevance of PRAME in breast cancer
  Breast Cancer Research and Treatment, 2007
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
  Proceedings of the National Academy of Sciences, 2001
• Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory Receptor
  Immunity, 1997